Vitrafy Life Sciences (ASX:VFY) has partnered with US healthcare organization Vitalant Innovation Center to address a "looming crisis" for red blood cell preservation, according to a Tuesday filing with the Australian bourse.
The companies aim to configure Vitrafy's cryopreservation ecosystem as a successor to legacy technology and products that will be discontinued from 2027, which poses a threat to red blood cell stockpiles, per the filing.
To support that objective, Vitrafy will initially place two cryopreservation freezing units at the Vitalant Innovation Center in Denver. The placement will not generate revenue, but the company expects the collaboration "to support broader market and government engagement toward a unified response," it said.